Pfizer and biontech submit application to u.s. fda for emergency use authorization of omicron ba.4/ba.5-adapted bivalent covid-19 vaccine

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced they have completed a submission to the u.s. food and drug administration (fda) requesting emergency use authorization (eua) of a booster dose of an omicron ba.4/ba.5-adapted bivalent covid-19 vaccine for individuals 12 years of age and older. the application follows guidance from the fda to include clinical data from the companies' bivalent omicron ba.1-adapted vaccine and pre-cli
BNTX Ratings Summary
BNTX Quant Ranking